The FDA granted orphan drug status to BioXcel Therapeutics' immuno-oncology drug BXCL701 as a treatment for acute myeloid leukemia. The drug is also being developed to treat a rare type of prostate cancer and pancreatic cancer.
Orphan Drug designation granted to BioXcel's AML drug candidate
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.